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conditions besides myositis and scleroderma
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Abstract
Introduction: Anti-PM/Scl antibodies are associated with polymyositis (PM)/systemic scleroderma (SSc) overlap
syndromes and are also found in other systemic autoimmune diseases. Although anti-PM/Scl reactivity is found in
3-11% of PM or SSc patients and in approximately 25% of PM/SSc overlap patients, previous large studies of
Japanese patients with scleroderma reported that anti-PM/Scl are not found in Japanese patients at all. The PM/Scl
autoantigen complex comprises 11–16 different polypeptides; ELISA with PM1-α peptide, which is a major epitope
of the PM/Scl complex, has frequently been used for the detection of these antibodies in recent studies. However,
no ELISA kit is commercially available in Japan.
Methods: In this study, we developed an immunoassay for measuring antibodies against recombinant PM/Scl-100
and PM/Scl-75 polypeptides, which are the two major targets of the complex, and we investigated their presence
in 600 Japanese patients with various systemic autoimmune conditions. Immunoprecipitation analysis using the
recombinants in addition to traditional radiolabeled cell extracts were also applied to ELISA-positive sera.
Results: In ELISA, 11 patients were positive for anti-PM/Scl-100 antibodies and 7 of these 11 patients were also positive
for anti-PM/Scl-75 antibodies. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled
cell extracts confirmed that 9 out of these 11 patients immunoprecipitated the typical sets of PM/Scl proteins. In total,
4/16 (25%) undifferentiated connective tissue disease (UCTD) patients, 3/126 (2.4%) dermatomyositis patients, 1/223
(0.4%) SSc patients, 1/88 (1.1%) Sjögren’s syndrome patients, 0/123 patients with systemic lupus erythematosus, 0/17
patients with overlap syndrome and 0/7 patients with PM were judged to be positive for anti-PM/Scl antibodies.
Conclusions: This is the first report of Japanese autoimmune patients with anti-PM/Scl antibodies. In Japanese patients,
anti-PM/Scl antibodies are only very rarely found, and they are not always specific for dermatomyositis (DM) or SSc; they
are also present in various autoimmune conditions with the highest prevalence being in UCTD. All anti-PM/Scl-positive
DM cases are complicated with interstitial lung disease and/or cancer, while no life-threatening involvement was found
in other anti-PM/Scl-positive cases. Further studies on larger cohorts are necessary to define the clinical significance of
anti-PM/Scl antibodies in autoimmune diseases.
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Introduction
A characteristic feature of patients with systemic auto-
immune diseases is the presence of autoantibodies in
their sera that target intracellular components [1]. Some
of these autoantibodies are useful diagnostic markers for
various systemic autoimmune diseases [1-3]. Some auto-
antibodies have great diversity in their prevalence among
different races and countries [4-6].
Anti-PM/Scl antibodies, first described as ‘anti-PM-1’ in
1977, were found in patients with overlap syndrome of
polymyositis (PM) and scleroderma (Scl) [7]. Anti-PM/Scl
antibodies produce a homogenous nucleolar pattern in in-
direct immunofluorescence (IIF) staining and recognize
the PM/Scl complex, which is the human counterpart of
the yeast exosome and consists of 11 to 16 polypeptides
[8]. Most anti-PM/Scl antibodies recognize two compo-
nents, PM/Scl-100 and PM/Scl-75 [9-11], and are found
mostly in patients with overlap syndrome (OL) of PM and
systemic scleroderma (SSc) (approximately 25%) [12], as
well as in PM or SSc patients (3% to 13%) [13]; however,
they are rarely found in other diseases, such as Sjögren’s
syndrome (SS) [14]. For the detection of anti-PM/Scl
antibodies, several techniques have been utilized: double
immunodiffusion, immunoprecipitation (IPP), enzyme-
linked immunosorbent assay (ELISA) and line immuno-
assay (LIA) [15]. ELISA using the PM-1α synthetic peptide,
a major epitope of PM/Scl-100 composed of an alpha
helical structure located at amino acid 231 to 245 of
PM/Scl-100 [16], was used in a recent multicenter
study that elucidated the diagnostic and prognostic
relevance of anti-PM/Scl antibodies in SSc clinics [17].
Unfortunately, this ELISA kit is not available in Japan.
The frequencies of some autoantibodies vary by eth-
nicity. For example, in a U.S. SSc cohort, in African-
American patients, anti-U3-RNP (fibrillarin) antibodies
were found in 30% of patients; meanwhile anti-Th/To
antibodies were found in only 4% [4]. In white patients,
however, anti-Th/To antibodies were found in 9%, whereas
anti-U3-RNP antibodies were found in only 3% [4]. An-
other example is that anti-RNA polymerase III antibodies
were less prevalent in French patients than in U.S. patients
[7]. Although anti-PM/Scl antibodies are found in certain
populations of patients in Western countries, as stated
above, clinical studies on Japanese autoimmune patients to
detect these antibodies have not been reported. Surpris-
ingly, in two large SSc cohorts from two Japanese centers,
no anti-PM/Scl-positive patients were found among 272
and 316 patients, respectively [18].
We recently developed a method that allows for the
rapid conversion of cDNAs to a chemiluminescent ELISA
to detect autoantibodies in human sera [19]. In this study,
we constructed an ELISA for measuring anti-PM/Scl-100
and also anti-PM/Scl-75 antibodies, in order to screen
these antibodies in 600 patients with various autoimmune
conditions from a single center in Japan, and we investi-
gated their clinical significance in Japanese patients.
Methods
Serum samples
Serum samples were collected from 600 Japanese pa-
tients, consisting of 223 with SSc, 126 with dermato-
myositis (DM), 123 with systemic lupus erythematosus
(SLE), 88 with SS, 17 with OL, 7 with PM and 16 with
undifferentiated connective tissue disease (UCTD), be-
tween 1994 and 2014 at Nagoya University Hospital. SSc
was diagnosed according to the classification of the
American College of Rheumatology (ACR) [20] or the
ACR/European League Against Rheumatism (EULAR)
2013 classification criteria [21]. Of the SSc patients, 185
were classified as diffuse cutaneous and 85 as limited
cutaneous, according to the criteria of LeRoy and col-
leagues [22]. The DM patients (76 with adult DM, 12
with juvenile DM (JDM) and 38 with clinically amyo-
pathic DM (CADM)) and PM patients fulfilled Bohan
and Peter’s criteria [23], except for CADM, which was
defined by Sontheimer’s criteria [24]. SLE was diagnosed
by the ACR criteria for SLE [25]. SS was diagnosed
based on Japanese diagnostic criteria [26]. OL, including
11 patients with PM+ SSc, was diagnosed as cases that
fulfilled the criteria for two systemic autoimmune diseases.
UCTD was diagnosed according to the preliminary classi-
fication criteria proposed by Mosaca and colleagues [27].
Interstitial lung disease (ILD) was diagnosed by chest
radiograph or chest computed tomography (CT) scan.
Clinical information was collected retrospectively by
reviewing their medical charts. Our cohort consisted of
newly diagnosed incipient patients, except for a few pa-
tients with juvenile DM. As for patients with UCTD,
serum samples were collected at the first visit. These pa-
tients were confirmed, by follow-up with doctors, as not
fulfilling the criteria for defined CTD for at least three
years from the beginning of symptoms according to the
criteria of UCTD [27]. As control samples, serum samples
from 72 healthy volunteers were also used. This study was
conducted with the approval of the ethics committees of
the Nagoya University Graduate School of Medicine and
the Kyoto University Graduate School of Medical Science.
All patients gave written consent to participate in the
study.
Recombinant antigens for ELISA and immunoprecipitation
The full-length cDNA clones of PM/Scl-100 (product No.
FXC03779) and PM/Scl-75 (product No. FXC22044) were
purchased from Flexi® ORF Clone (Promega, Madison,
WI, USA). Biotinylated recombinant proteins were pro-
duced from the cDNA, using the T7 Quick Coupled
Transcription/Translation System (Promega) according to
our published protocol [28]. In short, 800 μl transcription
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and translation (TnT) Quick Master Mix, 20 μl 1 mM me-
thionine, 30 μl transcend biotin-lysyl-tRNA, 120 μl water
and 30 μl DNA (1 μg/μl) were mixed and then incubated
at 30°C for 60 minutes.
ELISA
Antibodies against PM/Scl-100 and PM/Scl-75 were
tested by antigen-capture ELISA according to our
published protocols [19]. Briefly, a 96-well Nunc™
Immobilizer™ Streptavidin Plate (Thermo Scientific
Nunc, Roskilde, Denmark) was incubated with 1 μl/well of
in vitro TnT reaction mixture including biotinylated re-
combinant protein. Wells were then incubated with
1:1000 diluted sera and probed with anti-human immuno-
globulin G (IgG) antibody conjugated with horseradish
peroxidase (HRP) (Dako, Glostrup, Denmark) (1:30,000
dilution). After incubation with SuperSignal® ELISA Femto
Maximum Sensitivity Substrate (Thermo Scientific Pierce,
Rockford, IL, USA), the relative luminescence unit (RLU)
was determined using the GloMax®-Multi Detection Sys-
tem (Promega). Each serum sample was tested in dupli-
cate, and the mean RLU with the background subtracted
was used for data analysis. The RLU of the samples was
converted into units using a standard curve created by a
prototype positive serum. As a standard, the high-titer
anti-PM/Scl-100 (patient A in Figure 1) or anti-PM/Scl-75
(patient E in Figure 1) antibody-positive sera diluted 1:5
serially, starting from 1:500, was run. Units correlated with
the titers of antibodies: 1:500 dilution, 625 units; 1:2,500,
125 units; 1:12,500, 25 units; 1:62,500, 5 units; 1:312,500, 1
unit; 1:1,562,500, 0.2 units. The cutoff values (4.4 units for
anti-PM/Scl-100 antibody and 2.1 units for anti-PM/Scl-
75 antibody) were determined as the mean of the units ob-
tained from 36 control sera from healthy volunteers + 5
standard deviations (SD).
Immunoprecipitation
IPP was performed using TnT products as previously
described [28] and using radiolabeled extracts of HeLa
cells [29]. Prototype sera containing anti-PM/Scl, anti-
MDA5, anti-TIF1γ or anti-Mi-2 antibodies from TM’s
laboratory were also used.
Laboratory tests and serological assay
Sera that were positive for anti-PM/Scl by ELISA were
analyzed with an IIF laboratory kit using HEp-2 cells
(Fluoro HEPANA Test; MBL, Nagoya, Japan) [30]. The
samples were also screened by ELISA for antibodies
against CCP, SS-A, SS-B, U1-RNP, Sm, CENP-B, riboso-
mal P, aminoacyl tRNA synthetase (ARS) and ds-DNA
with commercial kits (MBL, Nagoya, Japan). This anti-
SS-A kit detects only anti-SS-A/Ro60 and not anti-SS-
A/Ro52/TRIM21.
Figure 1 Qualitative measurement of anti-PM/Scl antibodies in ELISA. ELISA units of anti-PM/Scl-100 and anti-PM/Scl-75 antibodies are shown for
a total of 600 serum samples from patients with various diseases. The antibody units are calculated from relative luminescence units using a
standard curve obtained from serial concentrations of serum samples: patient A’s serum for anti-PM/Scl-100 ELISA and patient E’s serum for
anti-PM/Scl-75 ELISA. The broken line indicates the cutoff value, which is the mean value of 36 healthy controls + 5 standard deviations. DM,
dermatomyositis; OL, overlap syndrome; PM, polymyositis; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc, systemic scleroderma;
UCTD, undifferntiated connective tissue disease.
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Statistical analyses
Data were statistically evaluated using SPSS Statistics
(IBM, Tokyo, Japan). Fisher exact probability tests were
used for comparison of frequencies. Mann–Whitney U
tests were used for comparison of ELISA units. P values
of less than 0.05 were considered significant.
Results
Measurement of anti-PM/Scl antibodies by ELISA
For the screening of anti-PM/Scl antibodies in large
numbers of serum samples, we developed an ELISA sys-
tem that uses biotinylated recombinant PM/Scl-100 and
PM/Scl-75. We screened a total of 600 serum samples
obtained from patients with various systemic auto-
immune diseases and an additional 36 serum samples
from healthy volunteers for both antibodies. Based on
the cutoff levels at 5 SDs above the mean value, nine
(1.5%) and seven (1.2%) patients were positive for anti-
PM/Scl-100 and anti-PM/Scl-75 antibodies, respectively
(Figure 1). Five patients (A, C, D, E and F) had both
antibodies, four (B, G, H and I) had only anti-PM/Scl-100
antibodies, and two (J and K) had only anti-PM/Scl-75
antibodies. When the cutoff was set at 3 SDs above the
mean value, one sample from a patient (L mentioned in
Figure 2) with overlap syndrome was just below the cutoff
for both antibodies. Subsequently, serum samples from
these 12 patients were used for immunoprecipitation
to confirm whether they were truly positive for the
anti-PM/Scl antibodies. An additional 36 samples from
healthy volunteers showed levels below the cutoff for
both antibodies.
Immunoprecipitation using recombinant PM/Scl protein
and radiolabeled cellular protein
After the initial screening by ELISA, we investigated anti-
bodies against PM/Scl in sera from 11 anti-PM/Scl-100
and/or anti-PM/Scl-75-positive patients and 1 equivocal
patient for their ability to immunoprecipitate biotinylated
recombinant PM/Scl-100 and PM/Scl-75 and radiolabeled
cellular PM/Scl. All nine anti-PM/Scl-100-positive sera in
ELISA immunoprecipitated biotinylated recombinant PM/
Scl-100, whereas five of the seven anti-PM/Scl-75-positive
sera in ELISA immunoprecipitated biotinylated recom-
binant PM/Scl-75 (Figure 2, TnT-IPP). Sera that were
anti-PM/Scl-75-positive in ELISA but -negative in IPP
(J and K) were negative for anti-PM/Scl-100 antibodies in
ELISA and IPP. Serum of patient L with equivocal ranges
in both ELISAs immunoprecipitated neither recombinant
PM/Scl-100 nor PM/Scl-75 (data not shown).
To determine whether the positive sera in ELISA
immunoprecipitate the PM/Scl complex, we applied
conventional IPP using radiolabeled HeLa cell extract
(Figure 2, HeLa-IPP). All nine sera (patients A to I) that
had reacted with the recombinant PM/Scl-100 also
immunoprecipitated a cellular 100-kDa protein. Eight of
these sera also immunoprecipitated a 75-kDa protein,
Figure 2 Detection of anti-PM/Scl antibodies in immuoprecipitation analysis. TnT-IPP: immunoprecipitation of biotinylated recombinant PM/Scl-100 and
PM/Scl-75. Recombinant proteins were subjected to 4% to 20% SDS-PAGE and analyzed by immunoblotting with streptavidin-alkaline phosphatase and
substrate. In., the input was half the dose for immunoprecipitation. Lanes A to K correspond to the anti-PM-Scl-100 and/or −75-positive patients shown in
Figure 1. Lane N: healthy control serum. HeLa-IPP: immunoprecipitation analysis using radiolabeled HeLa cell extracts. Lanes A to L correspond to the
patients shown in Figure 1 and Table 1. Lanes A to K correspond to anti-PM-Scl-100 and/or −75-positive patients shown in Figure 1. Lane M:
[Methyl-14C] methylated protein MW markers (PerkinElmer Japan, Yokohama, Japan). Lane L: anti-U1-RNP-positive serum with equivocal titers for both
antibodies in ELISA. Lanes 1 to 4 show the reference sera; lane 1, anti-PM/Scl-positive serum; lane 2, anti-MDA5-positive serum; lane 3, anti-TIF1-γ-positive
serum; lane 4, anti-Mi-2-positive serum. Arrow and arrowhead corrspond to the PM/Scl-100 and PM/Scl-75 antigens, respectively. IPP, immunoprecipitation;
TnT, in vitro translation and transcription product.
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but one another (patient I) did not. Two sera that were
positive only for anti-PM/Scl-75 in ELISA (patients J
and K) immunoprecipitated neither the 100-kDa nor the
75-kDa protein. The serum from an overlap syndrome
patient (L) with an equivocal level of both anti-PM/Scl-
100/75 antibodies in ELISA was negative in IPP. Accord-
ing to these results, eight sera (patients A to H) were
judged to be positive for anti-PM/Scl antibodies, as was
one other serum (patient I), which reacted to recombin-
ant PM/Scl-100 and which immunoprecipitated a 100-
kDa cellular protein.
Indirect immunofluorescence staining patterns of
anti-PM/Scl-100 and/or anti-PM/Scl-75-positive sera
In IIF analysis, the eight sera (patients A to H) that
immunoprecipitated the 100-kDa and 75-kDa proteins
showed nucleolar patterns (Table 1). The serum (patient
I) that only immunoprecipitated the 100-kDa protein
showed a speckled pattern without nucleolar staining.
Two sera (patients J and K) that immunoprecipitated
neither the 100-kDa nor the 75-kDa protein, also
showed no nucleolar patterns.
Clinical and laboratory data for anti-PM/Scl-positive
patients
The nine patients with anti-PM/Scl were four with
UCTD, three with DM (including one with CADM), one
with limited cutaneous SSc and one with SS. The clinical
features of these patients are summarized in Table 1.
The prevalence of anti-PM/Scl in UCTD (25%) is sig-
nificantly higher than that of DM (2.4%, P = 0.0032),
SSc (0.5%, P = 0.000066), SS (1.2%, P = 0.0018), SLE
(0%, P = 0.00012), OL (0%, P = 0.045) and healthy con-
trol (0%, P = 0.0067). Although the numbers of exam-
ined sera are very small, no patients with anti-PM/Scl
antibodies are found among patients with PM or OL.
Four patients with UCTD are clinically heterogeneous;
two are suspected of having SLE, one of having SS and
one of having rheumatoid arthritis (RA). All but one
are young adult women. No common clinical features,
including Raynaud’s phenomenon and abnormal nail-
fold capillaries, are present among these four patients.
Of the 126 DM patients, there are 8 anti-nucleolar
antibody (ANoA)-positive patients, of whom 3 patients,
all men, had anti-PM/Scl antibodies. Of the 123 anti-PM/
Scl-negative DM patients, only 32 are men (P = 0.020).
These three patients were complicated with ILD. The
clinical manifestations of ILD for these three patients
were improved by oral prednisolone and immunosup-
pressive agent therapy, and their ILD did not have a
fatal outcome. Additionally, the complication of in-
ternal malignancy (mesopharynx and prostate) was also
recognized in two patients three years before or after
the disease onset. ILD and internal malignancy are















A 52 F SS nucleolar, 1:2560 + / + + / + + / + dry eye, dry mouth
B 62 F lSSc nucleolar, 1:320 + / - + / - + / + Raynaud’s ph, sclerodactyly
C 54 M CADM nucleolar, 1:640
diffuse, 1:80
+ / + + / + + / + ILD, Gottron papules,
mechanic’s hands
D 69 M DM nucleolar, 1:640
diffuse, 1:80
+ / + + / + + / + ILD, Gottron sign, mechanic’s
hands, V-neck sign, dysphagia,
pharyngeal Ca
E 67 M DM nucleolar, 1:1280 + / + + / + + / + ILD, Gottron sign, Heliotrope rash
muscle weakness, prostate Ca
F 73 F UCTD nucleolar, 1:640 + / + + / + + / + ILD, dry eye, dry mouth
G 33 F UCTD nucleolar, 1:640
diffuse, 1:80
+ / - + / - + / + morning stiffness, polyarthralgia
H 31 F UCTD nucleolar, 1:160
speckled, 1:80
+ / - + / - + / + polyarthralgia, photosensitivity
I 31 F UCTD speckled, 1:80 + / - + / - + / - oral ulcer, photosensitivity
J 24 F UCTD diffuse, 1:640
cytoplasmic, 1:160
- / + - / - - / - SS-A dry eye, dry mouth
K 23 F SLE diffuse, 1:320
cytoplasmic, 1:80




a ‘diffuse’ and ‘speckled’ in the IIF pattern, respectively, refer to nuclear diffuse and nuclear speckled patterns. CADM, clinically amyopathic DM; Ca, carcinoma; DM,
dermatomyositis; ILD, interstitial lung disease; lSSc, limited cutaneous SSc; ph, phenomenon; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc,
systemic scleroderma; UCTD, undifferentiated connective tissue disease.
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more frequent in anti-PM/Scl-positive DM patients
than in anti-PM/Scl-negative DM patients, but not sig-
nificantly (P = 0.060 and P = 0.072, respectively).
Besides the three DM patients with ILD, one patient
who had UCTD was also complicated with ILD. Al-
though the anti-PM/Scl-100 ELISA units of these four
patients with ILD were not higher than those of five
anti-PM/Scl-positive patients without ILD (mean 26.7
versus 62.0), anti-PM/Scl-75 titers of the four patients
with ILD were significantly higher than those of five
patients without ILD (mean 86.0 unit versus 0.96 unit,
P = 0.027 by Mann–Whitney U test).
Discussion
The anti-PM/Scl antibody is a well-known ANoA and a
serological marker of OL and other systemic auto-
immune diseases such as SSc, PM and DM alone [15].
This antibody is common in the West. For example, it
Table 2 Frequencies of anti-PM/Scl antibodies in disease subsets
Frequencies of anti-PM/Scl antibodies in disease subsets
Study Marguerie Mahler Rozman Hanke Maes
Reference [13] [39] [40] [41] [42]
Year 1992 2005 2008 2009 2010
Country UK Various Europe Germany Belgium
Anti-PM/Scl detection CIE PM1-α ELISA LIA LIA PM1-α ELISA
Patient selection and numbers
of patients
1689 SLE 205 SSc 625 SSc 280 SScb 70 SSc
879 SSca 114 SLE 88 RA 66 SLE
256 PM or DM 40 PM 72 SLE 35 SS




Anti-PM/Scl-positive patients 27 PM (or DM)/SSc 22 PM/SSc (55%) 1 PM (7.7%) Anti-PM/Scl-75 Anti-PM/Scl-100 3 SSc (4.3%)
4 SSc 27 SSc (13%) 18 SSc (2.9%) 29 SSc (10%) 20 SSc (7.1%)
1 PM 3 PM (7.5%) 1 DM (1.7%) 3 RA (3.4%) 3 SLE (4.2%)
1 SLE (1.4%) 1 SS (2.0%)
Study Mierau Koschik Mehra D’Aoust Kazi Muro
Reference [31] [57] [58] [17] [18] The present study
Year 2011 2012 2013 2014 2014
Country Germany USA Australia Canada Japan Japan
Anti-PM/Scl detection ID ID LIA PM1-α ELISA IIP ELISA, IPP
Patient selection and numbers
of patients
863 SSc 2425 SSc 528 SSc 763 SSc Kanazawa cohort 223 SSc
316 SSc 126 DM
Keio cohort 123 SLE




Anti-PM/Scl-positive patients 42 SSc (4.9%) 75 SSc (3.1%) Anti-PM/Scl-75 55 SSc (7.2%) 0 4 UCTD (25%)
66 SSc (12.5%) 3 DM (2.4%)
Anti-PM/Scl-100 1 SS (1.1%)
26 SSc (4.9%) 1 SSc (0.4%)
aSince the numbers of myositis overlap patients were not given, the frequencies of the antibodies in disease subsets were not calculated; b51 overlap and 16
undifferentiated connective tissue disease patients were included.
CIE, counter immunoelectrophoresis; DM, dermatomyositis; ID, immunodiffusion; IPP, immunoprecipitation; LIA, line immunoassay; MCTD, mixed connective tissue
disease; PM, polymyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc, systemic scleroderma; UCTD, undifferentiated
connective tissue disease.
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was the third most-found, followed by anti-centromere
and anti-topoisomerase I antibodies, in a large cohort of
SSc patients in Germany [31]. However, large studies of
Japanese patients with SSc showed this antibody to be
absent [32,33], and a recent study noted that 0/588
Japanese patients with SSc had anti-PM/Scl antibodies
[18]. Large-cohort studies using sera from more than
200 connective tissue disease patients in the literature
are summarized in Table 2, although some studies with
mostly overlapped patients are omitted. Anti-PM/Scl
antibodies are strongly linked to HLA-DRB1*0301 [34],
which is very rarely found in Japanese, with a prevalence
of only 0.14%, according to an online database [35]
(HLA Laboratory, Kyoto, Japan); however, the contribu-
tion of this finding remains unknown. Since we had
found three patients to have strong ANoA in IIF analysis
during our recent studies on myositis-specific or associ-
ated autoantibodies [36-38], we aimed to investigate
anti-PM/Scl antibodies in our large cohort of systemic
autoimmune disease.
Although LIA for anti-PM/Scl-75 and −100 antibodies
and PM1-α ELISA have often been used recently
[16,31,39-43], the latter is not available in Japan and the
former is not cost-effective, costing around 13,000 yen/
sample (Cosmic Corporation, Tokyo, Japan). For our in-
house ELISA, the anti-PM/Scl-75 assay was found to be
inferior to the anti-PM/Scl-100 assay both in sensitivity
and specificity, according to the results of protein-IPP,
which is widely accepted as a reference method for detect-
ing several markers for SSc and PM/DM. Originally, most
PM/Scl-positive sera have been shown to contain anti-
PM/Scl-100 and about 50% to 60% of the sera have been
shown to react with PM/Scl-75 [11,12,44,45]. Raijmakers
and colleagues showed that PM/Scl-75 contains a previ-
ously unidentified N-terminal region that is important for
the antigenicity of the protein [46]. This longer form,
named PM/Scl-75c, was as reactive as PM/Scl-100 to sera
from PM/SSc overlap patients in ELISA (28% and 25%,
respectively) [46]. Subsequently, Hanke and colleagues
showed the prevalence of anti-PM/Scl-75c to be higher
than that of anti-PM/Scl-100 (10.4% versus 7.1%) in LIA
using sera from 280 SSc patients [41]. There are several
possible explanations for the lower prevalence of anti-PM/
Scl-75 than anti-PM/Scl-100 in this study. The cDNA in
this study, PM/Scl-75c-β, has a 17 amino acid insertion at
the C-terminus which could introduce conformational
changes in epitope [47]. In the study of Hanke and col-
leagues, recombinant PM/Scl-75 was expressed by a
baculovirus [41]. The discrepancies might also be due to
racial differences or clinical backgrounds. In a validation
study by Jaskowski and colleagues, the anti-PM/Scl-100
LIA had better agreement for the detection of anti-PM/Scl
with IPP as the reference method than with PM/Scl-75
LIA and PM1-α ELISA [48].
In this study, eight of nine anti-PM/Scl antibody-
positive sera exhibited nucleolar staining in IIF analysis.
Some studies have shown that anti-PM/Scl-positive sera
do not always demonstrate a nucleolar staining pattern
in IIF [16,17,47,49]. Interestingly, one ANoA-negative
serum with anti-PM/Scl reacted with PM/Scl-100 but
not with PM/Scl-75. Intramolecular epitope spreading
from the initial response against PM/Scl-100 to a suc-
cessive response by other exosomal components has
been recognized, as have many other autoantibody re-
sponses [50]. Figure 3 shows a four-way Venn diagram
depicting the overlap between anti-PM/Scl-100 by TnT-
IPP, anti-PM/Scl-75 by TnT-IPP, anti-PM/Scl by cellular
IPP and anti-nucleolar pattern by IIF. ANoA-positive
anti-PM/Scl antibodies all immunoprecipitated both
100- and 75-kDa proteins in HeLa-IPP, whereas only
one ANoA-negative anti-PM/Scl antibody (patient I)
immunoprecipitated only a 100-kDa protein in HeLa-
IPP. Since sera from Patient I immunoprecipitated sev-
eral other polypeptides, the nuclear speckled staining of
this patient in IIF may correspond to antibodies against
these proteins. Moreover, anti-PM1α reactivity has been
reported in apparently ANA-negative samples [16,17,49].
Although future studies are necessary to address whether
monospecific anti-PM/Scl-100 antibodies show nucleolar
staining in IIF, we can conclude that IIF is not a sensitive
immunoassay for the detection or screening of anti-PM/
Scl antibodies.
The findings of anti-PM/Scl antibodies in UCTD
patients are of clinical importance. The classification
criteria of UCTD are not well established [51]. Since
our UCTD patients were not diagnosed with definite
Figure 3 Venn diagram showing the overlap between anti-PM/Scl
antibodies by different assays. Anti-PM/Scl-100 and anti-PM/Scl-75
circles show the antibody-positive patiens determined by
immunoprecipitation with the corresponding recombinant protein.
The HeLa-IPP circle shows anti-PM/Scl-positive patients determined
by immunoprecipitation with HeLa cellular protein. Black dots show
the patients with both anti-75 kDa and anti-100 kDa antibodies, and
the gray dot shows the patient with only anti-75 kDa antibody
in HeLa-IPP. The ANoA circle shows the patients demonstrating
anti-nucleolar patterns as observed by indirect immunofluorecence.
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connective tissue disease even if the new set of RA cri-
teria [52] and the preliminary criteria for the very early
diagnosis of SSc [53] were used, we applied the prelim-
inary classification criteria of UCTD suggested by
Mosca and colleagues [27]. Four UCTD patients with
anti-PM/Scl were all so-called ‘stable UCTD’. Their dis-
ease courses were stable over a period of more than
three years without internal organ involvement, except
for one, whose ILD was nonspecific interstitial pneu-
monia that did not exacerbate for more than ten years.
Interestingly, Cordiali-Fei and colleagues [54] reported
that anti-PM/Scl responses were mainly associated with
Italian patients with UCTD, which was defined by the
same criteria used in our study. They found 5 patients
with anti-PM/Scl in 23 patients with UCTD (22%), a
frequency that is almost the same as that of our study.
Of second importance are the three anti-PM/Scl-
positive DM patients. Myalgia or muscle weakness varied,
and the levels of creatine kinase ranged from normal
levels to more than 2,000 IU/L. Patient C in this study is
the second reported case of CADM, to the best of our
knowledge, following the first case described by Lega
and colleagues [55]. A previous study of 20 PM/DM pa-
tients with anti-PM/Scl demonstrated that anti-PM-Scl is
not necessarily a marker for good prognosis in patients
with PM/DM, because lung and esophageal involvement
were found (in 75% and 20%, respectively), as was in-
ternal malignancy (in 15%) [56]. Also in our study, all
three patients were complicated with ILD and required
combined therapy of steroids and immunosuppressive
agents. Although they were all alive during the observa-
tion periods, the prognosis of ILD in anti-PM/Scl-posi-
tive DM patients cannot be determined due to the very
limited numbers examined and the limited observation
periods (maximum 45 months). Two of these patients
were also complicated with localized cancer without me-
tastasis. In a previous study, two out of twelve antibody-
positive patients with DM had mechanic’s hands [56].
Very interestingly, also in our study, two patients exhib-
ited mechanic’s hands in addition to sole hyperkeratotic
rhagadiform symptoms.
Conclusions
Our study of Japanese patients with various systemic auto-
immune diseases confirms that anti-PM/Scl antibodies
also exist in these patients. ELISA with PM/Scl-100 re-
combinant protein was useful in detecting anti-PM/Scl
antibodies. Anti-PM/Scl was not always specific for DM
or SSc; it was also present in various autoimmune condi-
tions, including UCTD. All the anti-PM/Scl-positive DM
cases were complicated with ILD and/or cancer, while no
life-threatening internal organ involvement was found in
other anti-PM/Scl-positive cases. Considering the higher
prevalence of anti-PM/Scl in UCTD, this autoantibody
may be more important in systemic autoimmune dis-
ease clinics than we expected. Further studies in larger
cohorts are necessary to define the clinical significance
of anti-PM/Scl antibodies in Japanese patients with
each autoimmune condition. Future collaborative stud-
ies for evaluating our sera with LIA and PM-1α ELISA
promise to be interesting.
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